Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to answer the following independent questions in the treatment of
mantle cell lymphomas:
- Can rituximab-fludarabine, cyclophosphamide (R-FC) improve the reduction of lymphoma
mass compared to rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone
(R-CHOP) and so become a new standard for initial cytoreductive therapy?
- Can maintenance with rituximab substitute the interferon maintenance and even improve
the progression free survival in patients after successful initial cytoreductive
therapy?
Phase:
Phase 3
Details
Lead Sponsor:
European Mantle Cell Lymphoma Network
Collaborators:
German Low Grade Lymphoma Study Group HOVON - Dutch Haemato-Oncology Association Lymphoma Study Association Nordic Lymphoma Group